SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (409)5/16/2003 6:10:56 AM
From: Icebrg   of 631
 
>>Something strange is going on???>>

[Thinking a little bit about the comparisons in dosing strength. Trying to answer my own question.]

Are the doses used in these two trials comparable? I.e does 2 mg per kg of Antegren correspond to 2 mg per kg of MLN02 in "strenght"? As they are both mAbs aiming for the same integrin (but not the same epitope) my guess would be that they are similar.

Well, as Antegren actually binds to two different integrins it (now) appears to me to be natural that more Antegren will be needed than MLN02 to achieve saturation-level of integrin-binding.

[Which leads on to the next train of thought]

Antegren clearly has a two uses. It might be useful both in the treatment of MS as well as IBD-deseases. Two conditions whose symptoms appear to be caused by overenthusiastic recruitment of leukocytes into the CNS and gut resp.

But, one has to guess that there should also a more normal level of trafficking. This recruitment pathway does not exist by chance. It most cases the leukocytes will do their work in the service of their host (i.e. us).

So, there should theoretically at least be a much larger risk for negative sideeffects when Antegren is used. Both on the CNS-side for Crohn's sufferers as well as in the "stomach" for patients with MS . Any thoughts from anyone on this?

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News